Problem of detection and pharmacological correction of anxious and depressive disorders in patients with type 2 diabetes mellitus
Yu.A. Sorokina (1), A.V. Zanozin (2), O.V. Zanozina (1, 3), G.P. Runov (1, 3)
1) Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia;
2) Narcological Hospital, Nizhny Novgorod, Russia;
3) Nizhny Novgorod Regional Clinical Hospital (NNRCH) n.a. Semashko, Nizhny Novgorod, Russia
Background. Depression and anxiety are frequent companions of chronic somatic diseases. The most acute question is about
the pharmacotherapy of these conditions in type 2 diabetes mellitus (DM2), when, due to the similarity of the clinical symptoms
and manifestations of anxious disorders, they are difficult to differentiate, and treatment compliance is violated. The presence
of anxiety and depressive disorders contributes to the progression of the underlying disease and its complications.
Objective. Evaluation of the incidence of anxiety and depressive disorders in DM1 and DM2 patients during planned hospitalization. Methods. Filling EQ5D5L and HADS questionnaires by patients (DM1 – 50 patients, DM2 – 47 patients) of School of Diabetes.
Results. Subclinical and clear signs of depression and/or anxiety were detected in all DM2 patients, while these indicators were within the normal range in DM1 patients. DM2 patients assessed their own quality of life significantly lower than DM1 patients.
Conclusion. DM2 patients have a high incidence of anxious and depressive disorders identified during screening. The timely detection and pharmacological support of such patients with such disorders can help to improve their quality of life and the effectiveness of glucose-lowering therapy due to their greater adherence to treatment.
Keywords: type 2 diabetes mellitus, screening for anxiety, screening for depression, personalized pharmacotherapy
About the Autors
Corresponding author: Olga V. Zanozina, MD, Professor of the Department of Hospital Therapy, Nizhny Novgorod State Medical Academy;
Head of the Department of Endocrinology, NNRCH n.a. Semashko, Nizhny Novgorod, Russia; e-mail: email@example.com
Address: 190, Rodionova Street, Nizhny Novgorod, 603126 Russian Federation